Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: No Intervention: Observational Cohort for Polycystic Ovary Syndrome (PCOS)

Introduction : Androgens play a vital role in the female reproductive system, influencing ovarian follicular development, oocyte quality, and ovarian responsiveness to controlled ovarian stimulation. The main circulating androgens include dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione (AD), testosterone (T), and dihydrotestosterone (DHT).

Official registry: https://clinicaltrials.gov/study/NCT07916909 · Women's Hospital School Of Medicine Zhejiang University · enrollment listed as 1,500

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 1,500 people at Hangzhou. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study

Interventions: No Intervention: Observational Cohort, No Intervention: Observational Cohort, No Intervention: Observational Cohort

Primary outcome (registry wording): Area Under the ROC Curve (AUC) of LC-MS/MS-derived Androgen Profiles for the Diagnosis of Polycystic Ovary Syndrome (PCOS)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 40 Years
  • Women only
  • PCOS group:Women who meet the Rotterdam diagnostic criteria (at least two of the following three features after excluding other endocrine disorders: oligo-ovulation/anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound)
  • Control group: Age-matched healthy women or women attending the clinic for routine gynecological check-ups who have regular menstrual cycles and show no clinical or biochemical signs of hyperandrogenism, and no polycystic ovarian morphology on ultrasound

Public study contact (from the registry)

Xiaoyu Tu

+86 13868092157

tuxiaoyu789@zju.edu.cn

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseNew Haven, Connecticut
Not a traditional drug phase: testing Vitamin D 4000IU daily for Polycystic Ovarian Syndrome in Adolescent Females

This study is a double blind, dummy treatment (placebo) controlled, randomly assigned trial of study subjects with PCOS and low vitamin D to 2 groups- dummy treatment (placebo) and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period

NCT04355572 · Official ClinicalTrials.gov record · Yale University

RecruitingPhase 3Aurora, Colorado
Phase 3: testing Semaglutide Injectable Product (Wegovy and/or Ozempic) for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

NCT05819853 · Official ClinicalTrials.gov record · University of Colorado, Denver

RecruitingNot a traditional drug phaseHouston, Texas
Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, body-mass index (BMI), and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

NCT05950282 · Official ClinicalTrials.gov record · Ali Chappell

FAQ about this NCT record

Is NCT07916909 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07916909?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07916909?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary